西罗莫司新剂型的研究概述  

Overview on the New Dosage Forms of Sirolimus

作　　者：潘明杰[1,2] 杜蓉[1] 陈鹰[1] 邵鸽 

机构地区：[1]广州军区武汉总医院药剂科,武汉430070 [2]湖北中医药大学药学院

出　　处：《中国药师》2016年第6期1183-1186,共4页China Pharmacist

摘　　要：20世纪90年代中期,人们发现西罗莫司对T淋巴细胞增殖有抑制作用,故将其用于抗肿瘤细胞的治疗。目前上市的西罗莫司剂型有胶囊剂、口服液、片剂,但由于西罗莫司脂溶性好,而水溶性较差,故其生物利用度不高,且容易发生不良反应。本文通过检索近几年Pubmed、Springer、CJFD、维普中文期刊数据库、万方数据库中收录的相关文献,综述西罗莫司新剂型的研究情况。以期为西罗莫司的深入研究提供参考依据。In the middle of 1990s, it was discovered that sirolimus had inhibitory effect on the proliferation of T lymphocytes, therefore, it is used for the treatment of anti-tumor cells. At present, the dosage forms of sirolimus are capsules, oral liquid and tab- lets. However, because of good fat-soluble and poor water-soluble property, its bioavailability is low with many side reactions. In order to provide reference for the further studies of sirolimus, the literatures in recent years were searched in Pubmed, Springer, C2FD, VIP Chinese periodical database and Wanfang data. and the research progress in the new dosage forms of sirolimus was summarized.

关 键 词：西罗莫司 免疫抑制药 新剂型 

分 类 号：R944[医药卫生—药剂学]